Table 2.
Overall survival in sarcoma patients undergoing ablation.
| Variable | Univariate | Multivariate | ||||
|---|---|---|---|---|---|---|
| Median (months) | p | Model coefficient | 95% CI | Hazard ratio | p | |
| Sex | 0.36 | |||||
| Male | 49.6 | |||||
| Female | 53.1 | |||||
| Age | 0.92 | |||||
| >50 years | 52.4 | |||||
| <50years | 55.9 | |||||
| Tumour size | 0.033 | 0.54 | 0.87–3.38 | 1.72 | 0.1159 | |
| ≤3 cm | 53.1 | |||||
| >3 cm | 31.6 | |||||
| Index tumour grade | 0.19 | |||||
| High | 53.1 | |||||
| Low | Not reached | |||||
| Histologic subtype | 0.17∗ | |||||
| Leiomyosarcoma | 55.9 | |||||
| GIST | 78.1 | |||||
| Liposarcoma | Not reached | |||||
| Chondrosarcoma | 24.3 | |||||
| Other | 46.9 | |||||
| Failed previous chemotherapy | 0.027 | −0.56 | 0.31–1.06 | 0.57 | 0.0749 | |
| No | 62.6 | |||||
| Yes | 33.2 | |||||
| Disease-free interval | 0.87 | |||||
| <12 months | 52.4 | |||||
| >12 months | 55.7 | |||||
∗Log-rank tests of no differences among categories vs. any differences among categories.